Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data

What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?

Om Podcasten

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.